Add to a list

Inactive Instrument

DECHRA PHARMACEUTICALS LIMITED Stock OTC Markets

DPHAY

US2434351043

OTC Markets Traded

Valuation: DECHRA PHARMACEUTICALS LIMITED

Market Cap	4.4B 5.94B 5.15B 4.83B 8.28B 566B 8.41B 56.95B 22.19B 284B 22.29B 21.83B 947B	P/E 2022	64.8x	P/E 2023	-150x
Enterprise Value	4.83B 6.52B 5.66B 5.31B 9.09B 622B 9.24B 62.52B 24.36B 312B 24.47B 23.96B 1,039B	EV / Sales 2022	5.8x	EV / Sales 2023	6.08x
Free-Float	-	Yield 2022	1.3%	Yield 2023	0.34%

* Estimated data More valuation ratios

Latest news : DECHRA PHARMACEUTICALS LIMITED

06-25	Dechra Opens New Global Headquarters in Boston and Invests $60,000 in Local Community Partnerships	CI
05-19	Dechra Veterinary Products LLC Announces FDA Approval Of Cosacthen Cosyntropin Injection For Canine Patients	CI
03-30	Dechra Pharmaceuticals Limited Announces Termination of Jonathan David Lang as Director, Effective March 31, 2026	CI
03-11	Dechra Announces Consolidation Of Its Existing U.S. Office Footprint In Kansas City, Kan. And Portland, Maine	CI
03-11	Dechra Announces Plans to Relocate Its Global Headquarters from Northwich, England, to Boston, Massachusetts	CI
25-10-13	Intervacc Extends Equine Strangles Vaccine Distribution Deal with Dechra Pharmaceuticals	MT
25-10-13	Intervacc and Dechra Extend Distribution Agreement for Intervacc's Equine Strangle Vaccine Strangvac by Two Years	CI
25-09-02	Dechra Pharmaceuticals Limited completed the acquisition of Invetx, Inc. from a group of shareholders for approximately $530 million	CI
25-08-18	Dechra Pharmaceuticals PLC Launches Strangvac in Spain, Portugal and Slovenia	CI
25-06-16	Vaxxinova GmbH acquired Poultry Vaccines Business of Dechra Pharmaceuticals Limited.	CI
25-05-05	Dechra Pharmaceuticals to Launch Intervacc's Horse Vaccine in Finland	MT
25-05-05	Dechra Pharmaceuticals plc Launches Strangvac in Finland	CI
24-07-17	Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.	CI

More news

Analysts' recommendations: DECHRA PHARMACEUTICALS LIMITED

23-06-27	Stifel Downgrades Dechra Pharmaceuticals to Hold from Buy, Lowers PT	MT
23-06-27	Analyst recommendations: Alphabet, Amgen, GSK, Moderna, Smiths Group...
23-06-27	UBS cuts BT'; HSBC starts Smiths with 'hold'	AN
23-03-07	Davy ups Purplebricks; JPMorgan cuts Clarkson	AN
23-01-12	UBS cuts Beazley; Berenberg likes Rio and BHP	AN

More recommendations

Press Releases: DECHRA PHARMACEUTICALS LIMITED

23-12-27	Form 8.5 (EPT/RI) - Dechra Pharmaceuticals plc	AQ
23-10-30	Dechra Pharmaceuticals : 30 October 2023 Annual Report 2023 (Online)	PU
23-10-17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023 ESEF XHTML	PU
23-10-17	Dechra Pharmaceuticals : 17 October 2023 Annual Report 2023	PU
23-09-06	Form 8.3 - Dechra Pharmaceuticals plc	AQ

More press releases

News in other languages: DECHRA PHARMACEUTICALS LIMITED

24-01-12	BOLETÍN MATINAL : 12 de enero de 2024
23-12-13	Pharma und Gesundheit: weitere Konsolidierung
23-12-12	Farma en gezondheid: consolidatie gaat door
23-12-11	Farmaceutica e salute: continua il consolidamento
23-12-11	Farmacia y salud: La consolidación continúa

More news

Managers and Directors: DECHRA PHARMACEUTICALS LIMITED

Manager	Title	Age	Since
Jesper Nordengaard CEO	Chief Executive Officer	-	2024-06-09
Paul Sandland DFI	Director of Finance/CFO	46	2019-04-02
Jamie Adams CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Paul Sandland BRD	Director/Board Member	46	2019-10-29
Lawson Macartney BRD	Director/Board Member	68	2016-11-30
Lisa Bright BRD	Director/Board Member	59	2019-01-31

More insiders

Dechra Pharmaceuticals PLC specializes in the manufacturing and marketing of veterinary pharmaceutical products. Net sales break down by family of products as follows: - companion animal products (74.6%); - food producing animal products (11.5%); - equine health products (7.3%); - animal feeds (5.1%); - other (1.5%): products manufactured by third parties. Net sales are distributed geographically as follows: the United Kingdom (8.5%), Germany (9.2%), Europe (31.2%), the United States (37.9%) and other (13.2%).

Employees

Sector

More about the company

	2022	2023
Net sales	682M 920M 798M 748M 1.28B 87.67B 1.3B 8.82B 3.44B 43.94B 3.45B 3.38B 147B	762M 1.03B 891M 836M 1.43B 97.92B 1.46B 9.85B 3.84B 49.07B 3.85B 3.77B 164B
Net income	58.2M 78.55M 68.12M 63.89M 109M 7.48B 111M 753M 293M 3.75B 295M 288M 12.52B	-27.9M -37.66M -32.65M -30.63M -52.48M -3.59B -53.31M -361M -141M -1.8B -141M -138M -6B
Net Debt	208M 281M 244M 229M 392M 26.77B 398M 2.69B 1.05B 13.42B 1.05B 1.03B 44.77B	430M 581M 503M 472M 809M 55.3B 822M 5.56B 2.17B 27.72B 2.18B 2.13B 92.49B

DECHRA PHARMACEUTICALS LIMITED Stock OTC Markets

Stocks